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Cerebral Cavernous Malformations: 
Review of the Genetic and  
Protein–Protein interactions 
Resulting in Disease Pathogenesis
Jacob F. Baranoski, M. Yashar S. Kalani, Colin J. Przybylowski and Joseph M. Zabramski*
Department of Neurosurgery, St. Joseph’s Hospital and Medical Center, Barrow Neurological Institute, Phoenix, AZ, USA
Mutations in the genes KRIT1, CCM2, and PDCD10 are known to result in the formation 
of cerebral cavernous malformations (CCMs). CCMs are intracranial lesions composed 
of aberrantly enlarged “cavernous” endothelial channels that can result in cerebral hem-
orrhage, seizures, and neurologic deficits. Although these genes have been known to 
be associated with CCMs since the 1990s, numerous discoveries have been made that 
better elucidate how they and their subsequent protein products are involved in CCM 
pathogenesis. Since our last review of the molecular genetics of CCM pathogenesis in 
2012, breakthroughs include a more thorough understanding of the protein structures of 
the gene products, involvement with integrin proteins, and MEKK3 signaling pathways, 
and the importance of CCM2–PDCD10 interactions. In this review, we highlight the 
advances that further our understanding of the “gene to protein to disease” relationships 
of CCMs.
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iNTRODUCTiON
Cerebral cavernous malformations (CCMs) are intracranial lesions comprised of low flow and 
abnormally dilated capillary endothelial channels with increased permeability that predispose 
these vessels to episodes of thrombosis and focal hemorrhage, resulting in seizures and neurologic 
deficits.
Loss-of-function mutations in the genes Krev interaction trapped 1 (KRIT1 or CCM1), cerebral 
cavernous malformation 2 (CCM2), and programed cell death protein 10 (PDCD10 or CCM3) 
result in the formation of CCMs. Although a role for these three genes in the formation of these 
intracranial vascular lesions has been established since the 1990s, additional works have further 
elucidated the molecular mechanisms by which mutations in these genes and the resultant aberrant 
proteins interact, leading to the formation of CCMs.
The three CCM proteins coded by KRIT1, CCM2, and PDCD10 form a trimeric protein 
complex. Germline loss-of-function mutations in any of these genes may lead to the formation 
Abbreviations: CCM, cerebral cavernous malformation; FAT, focal adhesion targeting; HP1, hydrophobic patch 1; ICAP1, 
integrin cytoplasmic-associated protein-1; MLC, myosin light chain; ROCK, Rho-associated coiled-coil-forming kinase; 
SMURF1, Smad ubiquitin regulatory factor 1.
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of CCMs. Therefore, it is reasonable to assume that a molecular 
pathway exists that requires all three proteins to function 
together correctly for proper cellular function. Moreover, 
research is demonstrating how each component protein is 
capable of interacting with numerous other signaling and 
cytoskeletal molecules allowing for a diverse range of functions 
in molecular signaling pathways via unique protein–protein 
interactions.
In this review, we highlight some of these recent advances 
that further our understanding of the “gene to protein to disease” 
relationships of CCMs. This work is meant to expand upon and 
to serve as an update to the previous review from this institution 
published in 2012 (1).
KRiT1 (CCM1)
In 1994, Kurth et al. were the first to begin successful mapping 
of a causative gene for CCMs (2). Utilizing linkage analysis, 
these authors identified the q11–q12 region of chromosome 
7, specifically a 33-centimorgan (cM) region from D7S502 to 
D7S479, as potentially being responsible for CCM formation in 
a large Hispanic family. Concurrently, Marchuk et al. identified 
linkage between CCM and a sequence on the proximal long arm 
of chromosome 7 between D7S502 and D7S515 (3), and Gunel 
et al. successfully identified the D7S699 locus as linked to CCM 
(4). The potential region for the precise location of the CCM1 
gene was further refined to a 4-cM segment of the human 7q21-
q22, bounded by D7S2410 and D7S689 (5, 6).
Krev interaction trapped 1 was subsequently identified as the 
CCM1 gene in an analysis of multiple affected Hispanic families 
(7, 8). This finding was confirmed in a 1999 study involving 
French families with hereditary CCMs (9).
Krev interaction trapped 1 encodes the 736-amino acid pep-
tide. It is the largest of the three CCM proteins and is comprised 
of an N-terminal Nudix domain with three NPxY/F motifs, an 
ankyrin repeat region, and a C-terminal FERM domain (band 4.1 
protein, ezrin, radixin, and moesin) (10). Although KRIT1 has no 
known catalytic activity, it binds and interacts with scaffolding 
and signaling molecules.
KRiT1 and integrin Activation
Krev interaction trapped 1 interacts with integrin cytoplasmic-
associated protein-1 (ICAP1) (10). Integrins are transmembrane 
receptors whose functions include cellular attachment to the 
extracellular matrix as well as established roles in cell-to-cell 
signal transduction, embryogenesis, and tissue formation and 
repair. ICAP1 is one of the few established suppressors of integrin 
activation (10, 11). The N-terminal of KRIT1 binds to ICAP1 via 
the first of its three NPxY/F motifs and an unpredicted binding 
motif encompassing residues H172 to R185 (10). Liu et al. dem-
onstrated that ICAP1 utilizes the same binding domain to interact 
with KRIT1 as it does with β-integrin peptides (10). Therefore, 
ICAP1 cannot bind to integrin and suppress its activation when 
it is bound to KRIT1, resulting in increased integrin activation 
while ICAP1 is bound to KRIT1.
Interestingly, it also appears that KRIT1 stabilizes ICAP1 and 
that the loss of KRIT1 results in decreased ICAP1 levels and, 
therefore, increased integrin activation (12). Faurobert et  al. 
found that the loss of KRIT1 or CCM2 resulted in ICAP1 desta-
bilization and a subsequent increase in β1 integrin activity (12). 
Furthermore, they found that endothelial cells that are lacking 
KRIT1 or CCM2 do not properly interact with the extracellular 
matrix, and that this anomalous interaction with the extracel-
lular matrix may impair endothelial barrier function and result 
in increased RhoA-dependent contractility.
It is possible that mutations leading to aberrant KRIT1–ICAP1 
interactions could produce abnormal integrin activation and 
consequently disrupt normal tissue development. Although the 
precise role of the KRIT1–ICAP1 interaction on integrin activity 
in endothelial cells has not been fully elucidated, it is clearly an 
area that warrants further investigation.
Work by Renz et  al. has demonstrated that CCM proteins 
are involved in the modulation of the β1-integrin signaling 
cascade that regulates angiogenesis (13). These authors showed 
that loss of CCM proteins in endothelial cells results in the 
β1-integrin-dependent overexpression of the transcription 
factor, Krüppel-like factor-2 (KLF2). This overexpression of 
KLF2 subsequently results in increased activation of epidermal 
growth factor-like domain-containing protein 7 (EGFL7) and 
angiogenesis. This work suggests that CCM proteins are critical 
regulators of endothelial quiescence, and that loss of proper 
CCM signaling can result in aberrant angiogenesis. It is possible 
that this CCM-mediated regulation of KLF2 is further regulated 
by a CCM2–MEKK3 [mitogen-activated protein kinase kinase 
kinase-3 (MAP3K3)] interaction (14–16).
Krev interaction trapped 1 localizes at endothelial cell–cell 
junctions. The loss of KRIT1 results in impaired endothelial 
cell–cell junctions and loss of integrity associated with increased 
Ras homolog gene family (member A), RhoA, and protein activ-
ity (17–20).
KRiT1 and the Heart of Glass Receptor
The heart of glass receptor (HEG) is a transmembrane protein 
that plays a role in cardiovascular development. The loss of HEG 
results in aberrant cardiovascular morphogenesis (19, 21). Work 
by Gingras et al. demonstrated that the C-terminal FERM domain 
of KRIT1 binds to HEG and that this interaction is critical for the 
proper localization of KRIT1 at endothelial cell–cell junctions 
(19). Inhibition of this interaction results in failure of KRIT1 to 
localize at the endothelial cell–cell junctions, which results in 
aberrant cardiovascular development.
Interestingly, recent work by Zheng et  al. demonstrated 
that postnatal mice with conditional knockout of HEG in 
endothelial cells do not form cavernous malformations (21). 
However, postnatal mice with conditional knockout of CCM2 
in endothelial cells rapidly develop CCMs in the central nerv-
ous system. These authors were also able to demonstrate the 
absence of HEG mutations in a cohort of human patients with 
sporadic CCMs (sporadic CCMs are single isolated lesions that 
occur in the absence of germline mutations in KRIT1, CCM2, 
or PDCD10). Together, these findings suggest that HEG–CCM 
interactions are critical for embryonic cardiovascular develop-
ment and growth and that CCMs arise due to postnatal HEG-
independent CCM signaling aberrations in the endothelium of 
the central nervous system.
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KRiT1 and Notch Signaling
Krev interaction trapped 1 is also linked to Notch signaling. 
Wustehube et al. found that KRIT1 inhibition results in decreased 
Notch pathway activity while KRIT1 overexpression leads to 
upregulation of the Notch pathway as demonstrated by increased 
DLL4 expression (22). This reduction in Notch signaling in 
KRIT1-deficient endothelial cells results in irregular vascular 
sprouting and abnormal angiogenesis. Schulz et al. demonstrated 
that silencing of KRIT1 in endothelial cells resulted in decreased 
Notch3 activity in cocultured brain pericytes (23). Additionally, 
these authors found that DLL4 proteins stimulated Notch3 recep-
tors on human brain pericytes and that activated Notch3 induced 
the expression of PDGFRB2, N-Cadherin, HBEGF, TGFB1, NG2, 
and S1P genes. Upregulated Notch3 signaling in pericytes pro-
moted proper pericyte–endothelial cell interactions, stimulating 
proper angiogenesis (23). Pericytes devoid of functional Notch3 
signaling failed to suppress aberrant angiogenesis adequately. 
Therefore, proper Notch–KRIT1 interactions and subsequent 
endothelial cell–pericyte interactions are important to maintain 
proper vascular development, and dysregulation of Notch signal-
ing and the Notch3–KRIT1 interaction may contribute to the 
pathogenesis of CCMs.
KRiT1 and Regulation of Reactive Oxygen 
Species
Krev interaction trapped 1 also interacts with pathways that 
regulate the degradation of reactive oxygen species. A lack of 
KRIT1 results in the decreased expression of superoxide dis-
mutase-2, a reactive oxygen species scavenging molecule, which 
leads to increased levels of reactive oxygen species, AKT (protein 
kinase B) phosphorylation, and AKT-dependent forkhead box 
protein O1 (FOXO1) phosphorylation (24).
Choquet et  al. have demonstrated that increased levels of 
reactive oxygen species and oxidative stress, as marked by 
deregulation of cytochrome P450, may contribute to increased 
severity of CCM disease (25). These authors found that patients 
with concomitant mutations in the cytochrome P450 family of 
proteins and CCMs tended to have more lesions, larger lesions, 
and higher rates of intracranial hemorrhage.
CCM2 and PDCD10
The identification of families with hereditary CCMs, but no 
KRIT1 mutations, highlighted the possibility of the involvement 
of genetic loci other than KRIT1 in the pathogenesis of CCMs (26, 
27). Indeed, evidence began to emerge that linked two additional 
chromosomal regions in families with CCMs – one segment on 
7p and one on 3q (26). The CCM2 gene was successfully mapped 
to 7p15-p13, spanning an 11-cM region between D7S2846 and 
D7S1818. Within in this region, Liquori et  al. identified eight 
genes that were the most likely to be involved in CCM pathogen-
esis, including one gene that contains a phosphotyrosine-binding 
domain and was predicted to interact with KRIT1 (28). In 2004, 
the CCM2 gene was confirmed by Denier et al. and was identified 
as being located on 7p13, containing 10 coding exons (27). CCM2 
codes for the 444-amino acid protein CCM2/malcavernin, which 
contains a predicted N-terminus phosphotyrosine-binding 
domain and a C-terminal helical domain (28, 29). Endothelial 
cells require CCM2 for proper cytoskeletal structure, cell–cell 
interactions, and vessel lumen formation via the interaction of 
many critical signaling pathways.
The third CCM locus, PDCD10/CCM3, is located on 3q25.2-
27. This locus was identified within a 22-cM interval flanked 
by D3S1763 and D3S1262 (26). The role of PDCD10 in CCM 
pathogenesis was first proposed in 2005 by Bergametti et al. (30). 
They screened 20 unrelated families with CCMs, but found no 
mutations in KRIT1 or CCM2.
Programed cell death protein 10, located on 3q26.1, is a highly 
conserved gene containing seven coding and three non-coding 
exons, which result in a 212-amino acid protein (PDCD10). 
This protein is ubiquitously expressed and has an N-terminal 
dimerization domain and a C-terminal focal adhesion targeting 
(FAT)-homology domain (31). PDCD10 is the third member of 
the CCM protein complex and binds directly to CCM2 as well as 
several other signaling molecules (31, 32).
CCM2, CCM2L, and interactions with the 
MeKK3 Pathway
One of the roles of CCM2 in the CCM signaling pathway is to 
solidify endothelial cell–cell junctions and stabilize vascular 
structures. A significant development in the study of CCM2 and 
its functions was the discovery of its paralog. Termed CCM2-
like (CCM2L), this peptide has a high sequence homology to 
CCM2 and is selectively expressed in endothelial cells during 
periods of angiogenesis (33). Although there appears to be some 
similarity in their functions, the loss of CCM2L in Xenopus (frog) 
results in a phenotype similar to that of CCM2 knockouts, and 
the CCM2L-null phenotype can be rescued by overexpression 
of CCM2 (34); the two molecules are not entirely homologous. 
Because the three CCM proteins bind to each other to form a 
trimeric complex, CCM2L directly competes with CCM2 for 
binding to KRIT1, and therefore, subsequently inhibits CCM2-
mediated endothelial cell–cell adhesion stability by uncoupling 
these upstream components of the CCM pathway from CCM3 
(33). Interestingly, CCM2L does not compete with CCM2 for 
binding to PDCD10. These results suggest that CCM2L and 
subsequent modulation of the CCM pathway are molecular 
mechanisms by which endothelial cells maintain vessel stability 
and induce postnatal vessel growth.
Work by Cullere et al. in 2015 further elucidated the relation-
ship between CCM2 and CCM2L and their mechanisms of action 
(15). These authors demonstrated that both CCM2 and CCM2L 
could bind to and inhibit MEKK3 in a complex with KRIT1. 
MEKK3 and its downstream targets and effectors function in 
key signaling pathways, including those involved in endothelial–
mesenchymal transition, cell proliferation, and cellular migration. 
Moreover, the MEKK3 pathway plays a critical role in early 
cardiovascular development (35). Binding of both CCM2 and 
CCM2L to MEKK3 inhibits its activation and prevents its ability to 
phosphorylate MEK5 (dual specificity mitogen-activated protein 
kinase kinase 5), a downstream target. Lack of CCM2 also results 
in increased activation of extracellular regulated kinase 5 (ERK5), 
a mitogen-activated protein kinase 5, in endothelial cells. ERK5 
is ubiquitously expressed in endothelial cells, where it is thought 
to play a role in cell survival and maturation. These findings 
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suggest that both CCM2 and CCM2L are capable of regulating 
the activity of MEKK3, and therefore augmenting multiple major 
signaling pathways that have essential cellular functions.
The mechanism of CCM2 interaction with MEKK3 was dis-
covered in 2015 by Wang et al. (16). They described the crystal 
structure of the C-terminus of the CCM2 peptide and found 
that it contains a five-helix domain followed by a C-terminal tail 
that forms a separate, isolated helix capable of interacting with 
the other five helical domains. Furthermore, they discovered 
that the MEKK3 N-terminal helix binds the C-terminus of the 
CCM2 peptide, successfully revealing the mechanism for CCM2-
MEKK3 interaction and signaling.
Zhou et  al. determined the role of CCM proteins in the 
MEKK3 pathway (14). They demonstrated that CCM deficiency 
results in increased endothelial cell expression of transcription 
factors KLF2 and KLF4 via lack of inhibition of the MEKK3 
signaling cascade. They also showed that exogenous inhibition of 
MEKK3 in CCM-deficient organisms is capable of rescuing the 
CCM-deficient phenotype.
CCM2–PDCD10 Binding and Mutual 
Complex Stabilization
Perhaps the most intriguing recent discovery involving the CCM 
proteins includes the interaction between CCM2 and PDCD10. 
The three CCM proteins bind together to form a trimeric mol-
ecule, and while the binding relationships between KRIT1 and 
CCM2 – and its paralog CCM2L – have been well described (33, 
34), the molecular mechanism and functional importance of the 
CCM2-PDCD10 binding were only recently identified. Draheim 
et al. successfully demonstrated both the mechanism of interac-
tion between the CCM2 and PDCD10 molecules and that this 
interaction is required for their activity (36).
The crystalline structure of PDCD10 has an N-terminal 
dimerization domain and a C-terminal FAT-homology domain. 
Within this FAT domain is a highly conserved surface termed 
“hydrophobic patch 1” (HP1) that is critical for PDCD10 binding 
with numerous molecules including CCM2 (31, 37). However, 
the mechanism by which this domain interacted with CCM2 was 
unknown. Draheim et  al. showed that the structure of CCM2 
contains short helical sequences called LD motifs, and it is at these 
LD motifs that CCM2 binds PDCD10 via its highly conserved 
HP1 region of the PDCD10 FAT domain (36). Furthermore, the 
authors demonstrated that this binding stabilizes the CCM2–
PDCD10 complex and prevents proteasomal degradation of the 
protein complex. The loss of proper binding of CCM2 to PDCD10 
due to aberrations in the binding domains results in abnormal 
endothelial cell function, demonstrating that these domains are 
both essential for CCM2–PDCD10 interaction, CCM protein 
signaling, and endothelial cell function (36).
ADDiTiONAL DeveLOPMeNTS
KRiT1, CCM2, PDCD10, and RhoA–ROCK 
Signaling
Loss of KRIT1 function results in impairment of endothelial 
cell–cell junctions, with a loss of integrity and an associated 
increase in RhoA activity (17–20). Activated RhoA levels are 
also increased in endothelial cells lacking the normal function of 
CCM2 or PDCD10 (17, 38–40).
Activated RhoA results in actin polymerization and stress 
fiber formation, in part via the RhoA effector molecule 
Rho-associated coiled-coil-forming kinase (ROCK). ROCK, 
a serine-threonine kinase, polymerizes actin and increases 
actomyosin contractility via inhibition of myosin light chain 
(MLC) phosphatase. Inhibition of any of the CCM proteins 
results in increased levels of phosphorylated MLC, increased 
stress fiber formation, and the inability of endothelial cells to 
properly migrate, form three-dimensional tubal structures, and 
create a stable impermeable monolayer (20, 39–41). All of these 
anomalies in CCM-knockout mice were successfully rescued by 
inhibition of ROCK, further supporting the role of RhoA–ROCK 
signaling in the CCM phenotype (20, 39–41).
The precise mechanism by which CCM proteins interact 
with the RhoA pathway remains to be fully elucidated. Some 
possibilities include the interaction of KRIT1 with β1 integrin 
signaling (10, 12).
Cerebral cavernous malformation 2 may selectively promote 
E3 ubiquitin ligase-mediated degradation of RhoA via interac-
tion with Smad ubiquitin regulatory factor 1 (SMURF1) (42). 
Crose et al. found that cells lacking CCM2 possessed increased 
levels of RhoA, but not increased levels of other known SMURF1 
substrates, indicating that disruption of CCM2 does not inhibit 
SMURF1 itself, but rather the interaction of SMURF1 with 
RhoA (42).
Zheng et  al. showed that RhoA activity increases when 
STK25 (a GCKIII serine-threonine kinase and known binding 
partner of PDCD10) is knocked down, which could be a potential 
mechanism for increased RhoA activation in PDCD10-deficient 
endothelial cells (38).
PDCD10 and Neuronal Migration
Additional functions of CCM proteins are being identified. Louvi 
et al. discovered that PDCD10 has a pivotal role in neuronal migra-
tion via suppression of RhoA signaling. They demonstrated that 
PDCD10 activity is required for proper radial glia and pyramidal 
neuron migration through the subventricular zone (43). Loss of 
PDCD10 resulted in dysregulation of the actin and microtubule 
cytoskeleton and adversely affected cellular morphology and 
migration. This dysregulation may be a result of CCM-mediated 
regulation of RhoA signaling.
PDCD10 Mutations Associated with 
increased CCM Severity
Although loss-of-function mutations in any of the three 
CCM genes may result in CCM formation, different muta-
tions result in varying degrees of disease severity. Patients 
with CCMs harboring PDCD10 mutations have a significantly 
greater disease burden and severity compared to those with 
KRIT1 or CCM2 mutations. Cigoli et  al. found that patients 
with PDCD10 mutations had an earlier onset of disease 
symptomology compared to those with KRIT1 or CCM2 
mutations. Shenkar et  al. demonstrated that patients with 
familial PDCD10 mutations had a significantly more aggressive 
clinical CCM disease phenotype than patients with KRIT1 
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or CCM2 familial disease or sporadic lesions (44). Patients 
with PDCD10 mutations had an increased number of lesions 
and also presented with lesion hemorrhages earlier in life. 
Moreover, these authors found additional PDCD10 aberra-
tions in addition to the CCMs, including scoliosis, cognitive 
disability, and skin lesions, further suggesting that PDCD10 
plays other roles in tissue development aside from endothelial 
cell formation (43, 44).
PDCD10 and Meningiomas
Programed cell death protein 10 mutations are becoming 
increasingly identified in other disorders of tissue develop-
ment. A particularly exciting discovery is the predisposition of 
patients with PDCD10 mutations to develop meningiomas in 
addition to CCMs. Several reports in the literature demonstrate 
that patients with familial PDCD10 mutations have developed 
late–onset meningiomas in addition to multiple CCMs (45–47). 
Such reports highlight the potential functional diversity of CCM 
proteins in tissue development.
endothelial-to-Mesenchymal Transition 
in CCMs and Potential Role of  
Anti-inflammatory Agents
Another recent intriguing development in the study of CCMs 
is the discovery that PDCD10-deficient endothelial cells in 
CCMs undergo endothelial-to-mesenchymal transformation 
(48). This transformation is the result of the loss of PDCD10-
mediated regulation and subsequent upregulation of β-catenin 
signaling. Bravi et al. also found that once this change occurred 
in the endothelial cells of CCMs, TGF-β/BMP signaling was 
subsequently required for the progression of the disease (48). 
The authors also found that this endothelial-to-mesenchymal cell 
transformation occurred in sporadic CCM lesions in addition to 
the familial and animal model lesions (49). While these findings 
are interesting from a pathogenic standpoint, they are even more 
intriguing because they suggest potential therapeutic options for 
the treatment and prevention of CCMs. Indeed, Bravi et al. found 
that the anti-inflammatory drugs sulindac sulfide and sulindac 
sulfone, which attenuate β-catenin transcription activity, reduced 
aberrant vascular malformations in a murine PDCD10-deficient 
model of CCMs (48).
CONCLUSiON
Significant research findings from 2000 to 2015 have further 
enhanced our understanding of the pathogenesis of CCM forma-
tion. The use of advanced sequencing technologies to character-
ize genomic mutations and the identification of new signaling 
pathways and protein–protein interactions have led to great 
strides in understanding the molecular genetics involved in the 
development of CCMs. However, many unanswered questions 
remain, and future studies are clearly needed to improve our 
understanding of CCM pathogenesis. “Gene to protein to disease” 
mechanisms involved in the pathogenesis of CCMs should shed 
further light on potential therapeutic targets.
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